Coherus Oncology Touts 90% Debt Cut, LOQTORZI Sales Surge, Sets 2026 Data Catalysts

Biopharmaceutical company highlights financial transformation, commercial progress, and upcoming clinical readouts for pipeline assets.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Coherus Oncology (NASDAQ:CHRS) executives said the company has moved quickly through a multi-year transformation toward becoming an 'innovative oncology company,' highlighting a sharply improved balance sheet, an accelerating commercial launch for its PD-1 therapy LOQTORZI, and upcoming clinical readouts for two pipeline assets in 2026.

Why it matters

Coherus Oncology's transformation highlights the company's shift from a biosimilar-focused business to an innovative oncology player, with a strengthened financial position to support its pipeline development. The commercial success of LOQTORZI and the potential of its pipeline assets, tagmokitug and casdozokitug, could position Coherus as a key player in the oncology space.

The details

Management said Coherus has reduced indebtedness by roughly 90% over the last couple of years, from about $480 million to $3.7 million in senior secured debt. The company cited its biosimilar divestiture process following the 2023 acquisition of Surface Oncology as enabling significant debt paydown and a $250 million addition to the balance sheet to support its oncology pipeline development. Coherus discussed the commercial launch of LOQTORZI in nasopharyngeal carcinoma (NPC), an area of unmet need, and said it has invested in data acquisition and sales efforts to identify and target diagnosed patients. The company also highlighted the clinical profile of LOQTORZI, including an overall survival benefit of 65 months versus about 34 months on chemotherapy alone. Coherus provided details on its pipeline assets, tagmokitug and casdozokitug, describing their unique mechanisms of action and potential to address limitations of current therapies. The company plans to pursue collaborations to share costs in pivotal trials for these assets.

  • Coherus said it now has $3.7 million in senior secured debt, down from about $480 million previously.
  • Coherus said it added $250 million to its balance sheet to support oncology pipeline development following its 2023 acquisition of Surface Oncology.
  • Coherus is evaluating dose levels 5 and 6 for dose optimization of tagmokitug in its phase I study.
  • Coherus said a randomized phase II study evaluating toripalimab plus or minus casdozokitug is ongoing, with an initial readout expected mid-year 2026.

The players

Coherus Oncology

A commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology.

Theresa LaVallee

Chief Scientific and Development Officer at Coherus Oncology.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.